How to buy Capricor Therapeutics shares

Capricor Therapeutics, Inc is a biotechnology business with stocks listed in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.

How to buy shares in Capricor Therapeutics

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Capricor Therapeutics. Find the share by name or ticker symbol: CAPR. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Capricor Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Capricor Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Capricor Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

US stocks

eToro Share Trading (US stocks)

Finder Award

Our top pick for

Cheap broker fees

IG Share Trading

Finder Award

Our top pick for

Long-term investing

CMC Markets Stockbroking

Finder Award

Capricor Therapeutics share price

Compare share trading platforms

Sort by:

Name	Product	Standard brokerage for US shares	Inactivity fee	Currency conversion fee	Markets
eToro Share Trading (US stocks) Finder Award		USD 0	USD 10 per month if there’s been no login for 12 months	0.50%	Forex, CFDs, US shares	Zero brokerage share trading on US stocks with trades as low as $50. Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider. Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.	Go to site More Info	Compare	loading Fetching your data...
CMC Markets Stockbroking Finder Award		USD 0	No	0.60%	ASX shares, Global shares, Forex, CFDs, Options trading, mFunds, ETFs, Warrants	$0 brokerage on global shares including US, UK and Japan markets. Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.	Go to site More Info	Compare	loading Fetching your data...
IG Share Trading Finder Award		USD 0	AUD 50 per quarter if you make fewer than three trades in that period	0.70%	ASX shares, Global shares, Forex, CFDs, Margin trading	$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares. Note: $10,000 deposit required to open account. Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.	Go to site More Info	Compare	loading Fetching your data...
Saxo Capital Markets (Classic account) Finder Award		USD 9.9	No	0.75%	ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading	High quality, low-cost brokerage on global share trading. Access up to 19,000 global stocks on 36 of the world’s major stock exchanges and enjoy some of the most competitive FX rates on the the market when you trade with Saxo Capital Markets.	Go to site More Info	Compare	loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

Is it a good time to buy Capricor Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Shorting Capricor Therapeutics shares

There are currently 489,136 Capricor Therapeutics shares held short by investors – that's known as Capricor Therapeutics's "short interest". This figure is 29.3% down from 691,935 last month.

There are a few different ways that this level of interest in shorting Capricor Therapeutics shares can be evaluated.

Capricor Therapeutics's "short interest ratio" (SIR)

Capricor Therapeutics's "short interest ratio" (SIR) is the quantity of Capricor Therapeutics shares currently shorted divided by the average quantity of Capricor Therapeutics shares traded daily (recently around 1.7 million). Capricor Therapeutics's SIR currently stands at 0.28. In other words for every 100,000 Capricor Therapeutics shares traded daily on the market, roughly 280 shares are currently held short.

However Capricor Therapeutics's short interest can also be evaluated against the total number of Capricor Therapeutics shares, or, against the total number of tradable Capricor Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Capricor Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Capricor Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0245% of the tradable shares (for every 100,000 tradable Capricor Therapeutics shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Capricor Therapeutics.

Find out more about how you can short Capricor Therapeutics stock.

Capricor Therapeutics share dividends

We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.

Have Capricor Therapeutics's shares ever split?

Capricor Therapeutics's shares were split on a 1:10 basis on 5 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.

Capricor Therapeutics share price volatility

Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as US$0.88 up to US$12.32. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 6.5011. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Capricor Therapeutics overview

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Capricor collaborates with Lonza for the development of CAP-1002, its cell therapy candidate for the treatment of Duchenne muscular dystrophy and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Frequently asked questions

• What percentage of Capricor Therapeutics is owned by insiders or institutions?

  Currently 2.527% of Capricor Therapeutics shares are held by insiders and 6.199% by institutions.

• When does the fiscal year end for Capricor Therapeutics?

  Capricor Therapeutics's fiscal year ends in December.

• Where is Capricor Therapeutics based?

  Capricor Therapeutics's address is: 8840 Wilshire Boulevard, Beverly Hills, CA, United States, 90211

• What is Capricor Therapeutics's ISIN number?

  Capricor Therapeutics's international securities identification number is: US14070B3096

• What is Capricor Therapeutics's CUSIP number?

  Capricor Therapeutics's Committee on Uniform Securities Identification Procedures number is: 14070B101